These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19528243)

  • 41. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
    Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
    Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
    Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
    PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study.
    Mottet C; Sieber CC; Nauer A; Drewe J; Fried R; Larsen F; Beglinger C
    Hepatology; 1998 Apr; 27(4):920-5. PubMed ID: 9537429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers.
    Drewe J; Sieber CC; Mottet C; Wullschleger C; Larsen F; Beglinger C
    Clin Pharmacol Ther; 1999 Apr; 65(4):413-9. PubMed ID: 10223779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study.
    Tesei A; Ricotti L; De Paola F; Casini-Raggi C; Barzanti F; Frassineti GL; Zoli W
    J Chemother; 2000 Oct; 12(5):421-30. PubMed ID: 11128563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.
    Kéri G; Erchegyi J; Horváth A; Mezõ I; Idei M; Vántus T; Balogh A; Vadász Z; Bökönyi G; Seprõdi J; Teplán I; Csuka O; Tejeda M; Gaál D; Szegedi Z; Szende B; Roze C; Kalthoff H; Ullrich A
    Proc Natl Acad Sci U S A; 1996 Oct; 93(22):12513-8. PubMed ID: 8901613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas.
    Wasko R; Jankowska A; Kotwicka M; Liebert W; Sowinski J; Warchol JB
    Neuro Endocrinol Lett; 2003 Oct; 24(5):334-8. PubMed ID: 14647007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells.
    Voellger B; Waldt N; Rupa R; Kirches E; Melhem O; Ochel HJ; Mawrin C; Firsching R
    J Neurooncol; 2018 Sep; 139(3):573-582. PubMed ID: 29872948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report.
    Shiraishi K; Akai T; Tomita T; Hayashi R; Minamisaka T; Kuroda S
    Neuropathology; 2024 Jun; 44(3):247-251. PubMed ID: 38099404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Experimental study of dually targeting gene therapy system for pituitary adenomas].
    Ma CY; Lu YC; Shi JX; Ren CC; Zhu JD; Gu JR
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(4):262-6. PubMed ID: 15854489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.
    Diaz-Rodriguez E; Garcia-Rendueles AR; Ibáñez-Costa A; Gutierrez-Pascual E; Garcia-Lavandeira M; Leal A; Japon MA; Soto A; Venegas E; Tinahones FJ; Garcia-Arnes JA; Benito P; Angeles Galvez M; Jimenez-Reina L; Bernabeu I; Dieguez C; Luque RM; Castaño JP; Alvarez CV
    Endocrinology; 2014 Nov; 155(11):4329-40. PubMed ID: 25137025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of MR spectroscopy and treatment approaches in a patient with extrapituitary growth hormone secreting macroadenoma.
    Kozic D; Medic-Stojanoska M; Ostojic J; Popovic L; Vuckovic N
    Neuro Endocrinol Lett; 2007 Oct; 28(5):560-4. PubMed ID: 17984954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of leptin on growth hormone secretion and apoptosis of GH3 cells].
    Liu YL; Zhong YQ; Chi SM; Zhu YL
    Sheng Li Xue Bao; 2005 Apr; 57(2):254-8. PubMed ID: 15830113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.